$VERX

DeStefano David sold $82K of VERX (indirect holdings)

DeStefano David sold 6,460 indirectly-held shares of Vertex, Inc. (VERX) at $12.75 on 2026-05-28.

Original reporting
SEC EDGAR · DeStefano David
Published Jun 1, 2026, 8:17 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 1, 2026, 8:38 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$VERX
Neutral
medium confidence
Mentioned
$VERX
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VERXNeutralLow
01

Why it matters

Traders may treat the disclosure as a minor sentiment datapoint; without accompanying operational news, it should not be weighted like a fundamental update.

02

Market read

Primarily a sentiment/positioning signal; limited incremental information for valuation.

03

What to watch

No 10b5-1 plan is indicated, but the filing alone doesn’t reveal intent, tax timing, or whether other insiders are buying/selling concurrently.

Relevance 6/10Novelty 3/10Timing: After-hours/filing disclosure on 2026-06-01 (SEC Form 4 filed 16:17:29 ET).

Background

The article summarizes an SEC Form 4 insider transaction for Vertex, Inc., showing a director’s open-market sale.

Company-level read

Ticker impact

$VERXNeutralMedium confidence
Context

Vertex director David DeStefano sold 6,460 shares in an open-market transaction totaling $82,365, disclosed via SEC Form 4.

Expected impact

Low near-term impact; any move is likely limited to intraday sentiment around the filing.

Evidence & confidence

The filing is an ownership-change disclosure with no stated new company event (no earnings, trial, deal, or guidance). The sale size is relatively small versus typical market capitalization, and there is no 10b5-1 plan stated.

Market effects

Minimal; this is company-specific insider activity without sector-wide read-through.

None expected beyond US biotech/healthcare sentiment.

None expected.

Counterpoint

The sale may be routine liquidity management (and could be consistent with non-informational motives), so price reaction may be overstated.

Key entities

  • Vertex, Inc.

    Public company whose director reported an open-market sale of shares via SEC Form 4.

  • David DeStefano

    Director who sold 6,460 shares at $12.75/share (total $82,365).

Related articles

$VERXMedAI 8/10

Vertex Q2 Earnings Call Highlights

Vertex (NASDAQ:VERX) said slower cloud conversion is a timing issue, with customers using mixed cloud and on-prem deployments. Management highlighted strong e-invoicing momentum ahead of France and Germany mandates, expecting e-invoicing to affect ARR in Q3 and more in Q4. Q3 guidance: revenue $208M-$211M, adj. EBITDA $55M-$57M; full-year revenue $825M-$830M and adj. EBITDA $206M-$210M.

$VERXMedAI 8/10

Why is Vertex stock sliding today?

Vertex Pharmaceuticals shares fell 12.8% after its post-close Q2 2026 results. The company reported EPS of $0.20 vs $0.19 consensus and revenue of $203.97M vs $202.29M forecast, but Q3 2026 revenue guidance of $208M-$211M (midpoint below ~$211.69M consensus) and free cash flow of $2.7M disappointed. Morgan Stanley downgraded to Equal Weight and cut its price target to $15 from $19.

$VERXMed

Vertex stock tumbles on cloud growth miss, price target cuts

Vertex Inc. (NASDAQ:VERX) shares dropped 13.2% after its Q2 results missed cloud growth expectations and analysts cut price targets. DA Davidson lowered its target to $12 from $15, citing slower cloud conversions and reduced FY26 cloud growth guidance to 18% from 25%. Other analysts also adjusted targets following guidance and deal-cycle comments.

$VERXMedAI 8/10

Vertex Announces Second Quarter 2026 Financial Results

Vertex, Inc. (NASDAQ: VERX) reported Q2 2026 results for the quarter ended June 30, 2026. Total revenue rose 10.5% to $204.0 million, with software subscription revenue up 10.7% to $174.8 million and cloud revenue up 17.9% to $101.7 million. Adjusted EBITDA increased to $51.0 million. Outlook: Q3 revenue $208.0-$211.0 million and adjusted EBITDA $55.0-$57.0 million; FY 2026 revenue $825.0-$830.0 million and adjusted EBITDA $206.0-$210.0 million.